Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-02
2007-10-02
Monshipouri, Maryam (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S324000
Reexamination Certificate
active
11323261
ABSTRACT:
Methods are described for preventing or reducing ischemia and/or systemic inflammatory response in a patient such as perioperative blood loss and/or systemic inflammatory response in a patient subjected to cardiothoracic surgery, e.g. coronary artery bypass grafting and other surgical procedures, especially when such procedures involve extra-corporeal circulation, such as cardiopulmonary bypass.
REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4118481 (1978-10-01), Schnabel et al.
patent: 4153687 (1979-05-01), Schnabel et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4609725 (1986-09-01), Brady et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5576294 (1996-11-01), Norris et al.
patent: 5635187 (1997-06-01), Bathurst et al.
patent: 5677146 (1997-10-01), Sprecher et al.
patent: 5786328 (1998-07-01), Dennis et al.
patent: 5795865 (1998-08-01), Markland et al.
patent: 5994125 (1999-11-01), Markland et al.
patent: 6004579 (1999-12-01), Bathurst et al.
patent: 6057287 (2000-05-01), Markland et al.
patent: 6333402 (2001-12-01), Markland et al.
patent: 0 621 870 (1997-05-01), None
patent: 0 621 871 (1997-07-01), None
patent: 739 355 (2004-09-01), None
patent: EP 0 285 123 (1988-10-01), None
patent: WO93/14120 (1993-07-01), None
patent: WO93/14121 (1993-07-01), None
patent: WO93/14122 (1993-07-01), None
patent: WO95/21601 (1995-08-01), None
Adelman et al., “Proteolysis of Platelet Glycoprotein Ib by Plasmin Is Facilitated by Plasmin Lysine-Binding Regions,”Blood, 68:1280-1284 (1986).
Albrecht et al., “Elastase Inhibition by the Inter-α-Trypsin Inhibitor and Derived Inhibitors of Man and Cattle,”Hoppe-Seyler's Z. Physiol. Chem., 364:1697-1702 (1983).
Albrecht et al., “Kunitz-Type Proteinase Inhibitors Derived by Limited Proteolysis of the Inter-α-Trypsin Inhibitor, IX[1-8],”Hoppe-Syler's Z. Physiol. Chem., 364:1703-1708 (1983).
Anba et al., “Improving the stability of a foreign protein in the periplasmic space ofEscherichia coli,” Biochimie, 70:727-733 (1988).
Angliker et al., “The synthesis of lysylfluoromethanes and their properties as inhibitors of trypsin, plasmin and cathespin B,”Biochem. J., 241:871-875 (1987).
Atherton et al., “Peptide synthesis. Part 2. Procedures for Solid -phase Synthesis using Nα-Fluorenylmethoxycarbonylamino-acids on Polyamide Supports. Synthesis of Substance P and of Acyl Carrier Protein 65-74 Decapeptide,”J. Chem. Soc. Perkin Trans., 1:538-546 (1981).
Auerswald et al., “Expression, Isolation and Characterization of Recombinant [Arg15,Glu52]Aprotinin,”Bio. Chem. Hoppe-Seyler, 369:(Suppl)27-35 (1988).
Balduyck et al., “Human Urinary Proteinase Inhibitor: Inhibitory Properties and Interaction with Bovine Trypsin,”Bio. Chem. Hoppe-Seyler, 366:9-14 (1985).
Baneyx and Georgiou, “In Vivo Degradation of Secreted Fusion Proteins by theEscherichia coliOuter Membrane Protease OmpT”J. Bacteriol., 172:491-494 (1990).
Baneyx and Georgiou, “Construction and Characterization ofEscherichia coliStrains Deficient in Multiple Secreted Proteases: Protease III Degrades High-Molecular-Weight Substrates In Vivo,”J. Bacteriol., 173:2696-2703 (1991).
Berndt et al., “Designed Replacement of an Internal Hydration Water Molecule in BPTI: Structural and Functional Implications of a Glycine-to-Serine Mutation,”Biochem., 32:4564-4570 (1993).
Bhoola et al., “Bioregulation of Kinins: Kallikreins, Kininogens, and Kininases,”Pharmacological Reviews, 44:1-80 (1992).
Browne et al., “Expression of Recombinant Human Plasminogen and Aglycoplasminogen in HeLa Cells,”GeneBank, Accession No. M74220 (1991).
Broze et al., “Regulation of Coagulation by a Multivalent Kunitz-Type Inhibitor,”Biochem., 29:7539-7546 (1990).
Brus et al., “Disease Severity is Correlated With Plasma Clotting and Fibrinolytic and Kinin-Kallikrein Activity in Neonatal Respiratory Distress Syndrome,”Pediatr. Res., 41:120-127 (1997).
Budavari, ed., Merck Index, 11thEdition, ISBN 911910-28-X, entries 923, 1745, 2740, 7425 (1989).
Chung et al., “Human Plasma Prekallikrein, a Zymogen to a Serine Protease That Contains Four Tandem Repeats,”GenBank, Accession No. P03952 (1995).
Colman et al., “Activation of the Kallikrein-Kinin System in Arthritis and Enterocolitis in Genetically Susceptible Rats: Modualtion by a Selective Plasma Kallikrein Inhibitor,”Proc. Assoc. Am. Physicians, 109:10-22 (1997).
Cumming and Nimmo, “Hemodynamic, Renal, and Hormonal Actions of Aprotinin in an Ovine Model of Septic Shock,”Crit. Care Med., 20:1134-1139 (1992).
Currie, B. “Design and Synthesis of a Bicyclic Non-Peptide β-Bend Mimetic of Enkephalin,”Tetrahedron, 49:3489-3500 (1993).
DeLa Cadena et al., “Role of Kallikrein-Kinin System in the Pathogenesis of Bacterial Cell Wall-Induced Inflammation and Enterocolitis,”Transact. Assoc. Am. Physicians, 105:229-237 (1992).
DeLa Cadena et al., “Inhibition of Plasma Kallikrein Prevents Peptidoglycan-induced Arthritis in the Lewis Rat,”FASEB J., 9:446-452 (1995).
Dennis and Lazarus, “Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa, (I. Potent Inhibitors Selected from Libraries by Phage Display),”J. Biol. Chem., 269:22129-22136 (1994).
Dennis and Lazarus, “Kunitz Domain Inhibitors of Tissue Factor-Factor VIIa, (II. Potent and Specific Inhibitors by Competitive Phage Selection),”J. Biol. Chem., 269:22137-22144 (1994).
Dennis et al., “Potent and Selective Kunitz Domain Inhibitors of Plasma Kallikrein Designed by Phage Display,”J. Biol. Chem., 270:25411-25417 (1995).
Diaz et al., “The Design of Water Soluble β-Sheet Structure Based On a Nucleation Strategy,”Tetrahedron, 49:3533-3534 (1993).
DiMaio et al., “A new class of potent thrombin inhibitors that incorporates a scissile pseudopeptide bond,”FEBS Lett., 282(1):47-52 (1991).
Eigenbrot et al., “Structural Effects Induced by Removal of a Disulfide-Bridge: The X-ray Structure of the C30A/C51A Mutant of Based Pancreatic Trypsin Inhibitor at 1.6 Å,”Protein Engineering, 3:591-598 (1990).
Ellis et al., “The Urokinase Receptor: Involvement in Cell Surface Proteolysis and Cancer Invasion,”Ann. NY Acad. Sci., 667:13-31 (1992).
Fidler and Ellis, “The Implications of Angiogensis for the Biology and Therapy of Cancer Metastasis,”Cell, 79:185-188 (1994).
Fields and Noble, “Solid Phase Peptide Synthesis Utilizing 9-fluorenylmethoxycarbonyl Amino Acids,”Int. J. Pep. Pro. Res., 35:161-214 (1990).
Fraedrich et al., “Reduction of Blood Transfusion Requirement in Open Heart Surgery by Administration of High Doses of Aprotinin-Preliminary Results,”Thorac. Cardiovasc. Surg., 37:89-91 (1989).
Freidinger et al., “Protected Lactam-Bridged Dipeptides for Use as Conformational Costraints in Peptides,”J. Org. Chem., 47:104-109 (1982).
Gardell, “The Search for the Ideal Thrombolytic Agent: Maximize the Benefit and Minimize the Risk,”Toxicol. Pathol., 21(2):190-198 (1993).
Girard et al., “Functional Significance of the Kunitz-type Inhibitory Domains of Lipoprotein-Associated Coagulation Inhibitor,”Nature, 338:518-520 (1989).
Girard et al., “Structure of the Human Lipoprotein-associated Coagulation Inhibitor Gene,”J. Biol. Chem., 266:5036-5041 (1991).
Hoover et al., “Amino Acids of the Recombinant Kringle I Domain of Human Plasminogen That Stabilize Its Interaction with ω-Amino Acids,”Biochemistry, 32:10936-10943 (1993).
Hortin and Trimpe, “Allosteric Changes in Thrombin's Activity Produced by Pep
Hirani Shirish
Ladner Robert C.
Ley Arthur C.
Williams Anthony
Dyax Corp.
Fish & Richardson P.C.
Monshipouri Maryam
Tsay Marsha
LandOfFree
Prevention and reduction of blood loss does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and reduction of blood loss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and reduction of blood loss will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3871854